Weekly Digest – February 2026 Weekly Digest – February 2026 24 February 2026: Aktis Oncology receives U.S. FDA Fast Track Designation for AKY-1189, a nectin-4 miniprotein radioconjugate Aktis Oncology announced that the U.S. FDA has granted Fast Track designation to […]
Weekly Digest – February 2026 Weekly Digest – February 2026 25 February 2026: Kivu Bioscience announced HREC approval and Clinical Trial Notification (CTN) clearance in Australia to initiate a first-in-human clinical trial for KIVU-305 Kivu Bioscience announced new preclinical data […]
Weekly Digest – February 2026 Weekly Digest – February 2026 24 February 2026: Bispecific ADC Iza-bren meets both primary endpoints, significantly improving PFS and OS in unresectable or advanced/metastatic triple-negative breast cancer post-taxane failure Sichuan Baili Tianheng Pharmaceutical announced that […]
Weekly Digest – February 2026 Weekly Digest – February 2026 25 February 2026: IDEAYA Biosciences announces first-patient-in for Phase 1 trial of IDE034, a potential first-in-class B7H3/PTK7 bispecific TOP1 ADC IDEAYA Biosciences announced that the first patient has been enrolled […]
Weekly Digest – February 2026 Weekly Digest – February 2026 26 February 2026: Molecular partners signs development agreement with Eckert & Ziegler for targeted alpha radiotherapeutics Molecular Partners announced a development agreement with Eckert & Ziegler to support the advancement […]
Weekly Digest – February 2026 Weekly Digest – February 2026 24 February 2026: Ligachem Biosciences expands ADC pipeline with new NovaRock antibody license LigaChem Biosciences announced that it has signed a new technology licensing agreement with U.S.-based NovaRock Biotherapeutics to […]
